CaTe Inc.

CaTe Inc. (株式会社CaTe) is a Tokyo-based healthcare technology company whose stated mission is to build mechanisms that deliver needed medical care to people who cannot fully access it because of travel distance, time constraints or the difficulty of sustaining treatment. Its work is organized around three connection themes: linking patients with the range of medical professionals involved in their care, linking medical care with patients' everyday lives outside the hospital, and carrying health outcomes forward over time.

The company's research and development starts from the field of cardiac rehabilitation, combining clinical expertise with technology so that cardiac rehabilitation can be continued at home. Named functional areas include exercise therapy, dietary therapy, medication management, remote monitoring, remote coaching and patient education, delivered with an application acting as a hub and AI plus medical content used to support daily care. The company also enables information sharing with family members living apart from the patient, and frames its rationale around the observation that cardiac disease frequently leads to rehospitalization or deterioration after discharge.

Latest developments

In December 2025 CaTe announced the final close of its Series B, totalling JPY 1.73 billion. In January 2026 it was selected for the PCA phase of NEDO's DTSU program, bringing cumulative funding to JPY 3.5 billion to advance clinical trials and global expansion of its cardiac rehabilitation medical device. In June 2026 the company completed enrollment of the first patient in the clinical trial of its cardiac disease management program medical device.